Search

• Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

  Media

  ViiV announced the FDA has approved Juluca®, complete regimen for the maintenance treatment of HIV-1 infection in virologically suppressed..

  https://www.gsk.com/en-gb/media/press-releases/juluca-approved-in-us-as-first-2-drug-regimen-once-daily-single-pill/

  First published: 21 November 2017

• ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe

  Media

  ViiV Healthcare announced that the European Committee for Medicinal Products for Human Use issued a Positive Opinion for Juluca.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/

  First published: 23 March 2018

• Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial

  Media

  Healthcare workers among those to be vaccinated in large-scale trial involving up to 30,000 people due to start in the coming weeks

  https://www.gsk.com/en-gb/media/press-releases/major-milestone-for-gsknih-candidate-ebola-vaccine-as-first-doses-shipped-to-liberia-for-use-in-phase-iii-clinical-trial/

  First published: 23 January 2015

• GSK announces major new commitment to Asia

  Media

  GlaxoSmithKline (GSK) is strengthening its presence in Singapore by establishing a new global headquarters for Asia

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-major-new-commitment-to-asia/

  First published: 10 March 2015

• GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour

  Media

  GSK today announced the start of a phase III programme to evaluate the efficacy of retosiban, an investigational oxytocin antagonist.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-to-evaluate-retosiban-for-spontaneous-preterm-labour/

  First published: 17 March 2015

• GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma

  Media

  GSK and THRX announced the outcome of the joint meeting for a once-daily inhaled treatment for asthma in patients aged 12 years and older.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-outcome-of-us-fda-advisory-committee-on-breo-ellipta-in-asthma/

  First published: 19 March 2015

• GSK’s 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US

  Media

  GSK is encouraging scientists to submit their novel early drug discovery research proposals into its Discovery Fast Track Challenge

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-2015-discovery-fast-track-challenge-seeks-early-drug-discovery-partnerships-with-academics-in-europe-canada-and-us/

  First published: 24 March 2015

• FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

  Media

  GSK and THRX announced approved once-daily treatment of asthma in patients aged 18+ BreoEllipta is not for the relief of acute bronchospasm.

  https://www.gsk.com/en-gb/media/press-releases/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/

  First published: 30 April 2015

• GSK announces outcome of US FDA Advisory Committee recommending approval of mepolizumab for the treatment of adults with severe asthma

  Media

  GSK announced outcome regarding the BLA for mepolizumab as an add-on maintenance treatment for severe asthma with eosinophilic inflammation.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-outcome-of-us-fda-advisory-committee-recommending-approval-of-mepolizumab-for-the-treatment-of-adults-with-severe-asthma/

  First published: 11 June 2015

• New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression

  Media

  ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study

  https://www.gsk.com/en-gb/media/press-releases/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/

  First published: 23 September 2015